Tyra Biosciences (TYRA) Stock Price, News & Analysis

Company Overview

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection.

Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.

Key Stats

• Today's Range: $33.03 to $35.54
• 50-Day Range: $31.58 to $39.61
• 52-Week Range: $8.75 to $40.65
• Volume: 503,511 shs
• Average Volume: 986,824 shs
• Market Capitalization: $2.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.50
• Consensus Rating: Moderate Buy

Tyra Biosciences Stock Analysis - MarketRank™

Tyra Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 510th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Tyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 1 strong buy rating, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Tyra Biosciences has a consensus price target of $46.50, representing about 37.0% upside from its current price of $33.93.

Amount of Analyst Coverage

Tyra Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.42) to ($2.68) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tyra Biosciences is -16.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tyra Biosciences is -16.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tyra Biosciences has a P/B Ratio of 6.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TYRA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tyra Biosciences does not currently pay a dividend.

Dividend Growth

Tyra Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Tyra Biosciences this week, compared to 2 articles on an average week.

MarketBeat Follows

5 people have added Tyra Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $528,486.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TYRA Stock Analysis - Frequently Asked Questions

How have TYRA shares performed this year?

Tyra Biosciences' stock was trading at $26.29 at the beginning of the year. Since then, TYRA stock has increased by 29.1% and is now trading at $33.93.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences, Inc. (NASDAQ:TYRA) issued its quarterly earnings results on Monday, March, 2nd. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.03.

When did Tyra Biosciences IPO?

Tyra Biosciences (TYRA) raised $162 million in an initial public offering on the week of September 13th 2021. The company issued 10,800,000 shares at a price of $14.00-$16.00 per share.

Who are Tyra Biosciences' major shareholders?

Top institutional shareholders of Tyra Biosciences include Canaan Partners XI LLC (1.26%), Bank of New York Mellon Corp (0.12%), Strs Ohio (0.03%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Robert J More, Todd Harris, Nina S Kjellson, Daniel Bensen, Gilla Kaplan and Alan Fuhrman.
View institutional ownership trends.

How do I buy shares of Tyra Biosciences?

Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tyra Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 3/02/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TYRA
• CIK: 1863127
• Web: www.tyra.bio
• Phone: 619-728-4760
• Fax: N/A
• Employees: 20
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Tyra Biosciences: $46.50
• High Price Target: $56.00
• Low Price Target: $35.00
• Potential Upside/Downside: +37.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$119.95 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.17%
• Return on Assets: -38.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.67
• Quick Ratio: 14.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.86 per share
• Price / Book: 6.98

Miscellaneous

• Outstanding Shares: 59,490,000
• Free Float: 52,049,000
• Market Cap: $2.02 billion
• Optionable: Optionable
• Beta: 0.79